Author: Dino Mustafić

March 4, 2021 Off

Nanobiotix, PharmaEngine conclude collaboration

By Dino Mustafić

NANOBIOTIX,a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the Company has reached an agreement with PharmaEngine to terminate the License and Collaboration agreement that the Company and PharmaEngine entered into in August 2012.

February 18, 2021 Off

Navamedics revenues up 17% in Q4 2020

By Dino Mustafić

Navamedic ASA said Thursday it grew revenues by 17% in the fourth quarter of 2020 compared to the same quarter last year, as it reported revenues of NOK 55.3 million in the fourth quarter of 2020 with an EBITDA of negative NOK 3.7 (€5.4) million driven by both new product launches and investments in further growth initiatives.

February 16, 2021 Off

Novavax’ vaccine in South Korea

By Dino Mustafić

Novavax and SK Bioscience, a vaccine business subsidiary of SK Group, today announced an expanded collaboration and license agreement to include for Bioscience a license to make and sell Novavax’ Covid-19 vaccine to the Korean government.

February 15, 2021 Off

Basilea divests its Chinese R&D subsidiary to PHT International

By Dino Mustafić

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into an agreement to divest its Chinese research and development (R&D) subsidiary Basilea Pharmaceutica China Ltd. (“BPC”), by selling BPC’s parent company BPh Investitionen Ltd. to the U.S.-based custom manufacturing organization PHT International Inc. (“PHT”).